Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences High-Value Diagnostics

Cloud Paweletz's Biography



Cloud Paweletz, Head of the Translational Research Laboratory, Dana Farber Cancer Institute

Dr. Paweletz is head of the Translational Research Laboratory (TRL) of the Belfer Institute for Applied Cancer Science at the Dana Faber Cancer institute. He joins the Belfer Institute from Merck & Co., Inc., where he held positions of increasing responsibility for more than 10 years, most recently serving as externalization lead and proteomics site lead for the Department of Molecular Biomarkers. At Merck, Dr. Paweletz successfully built platforms to look at disease biomarkers in body fluids and oversaw research activities spanning the spectrum from early-stage discovery to the clinic. Prior to that, he was a post-doctoral fellow in the department of physiology at the Uniformed Services University School of Medicine in Bethesda, and a research fellow in the laboratory of pathology at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda.

Cloud Paweletz Image

Monitoring Cancer Through the Blood

Monday, 16 November 2015 at 16:30

Add to Calendar ▼2015-11-16 16:30:002015-11-16 17:30:00Europe/LondonMonitoring Cancer Through the BloodSELECTBIOenquiries@selectbiosciences.com

Genotype-directed targeted therapies are revolutionizing cancer care. Genomic alterations in genes such as EGFR, ALK, KRAS, and BRAF have been validated as powerful predictive biomarkers in the management of non-small cell lung cancer (NSCLC), colorectal cancer, and melanoma; testing for these mutations is currently standard to personalize treatment decisions. The challenges associated with routine use of NGS include availability of adequate tumor specimens, slow turnaround time, and evolving tumor biology in response to treatment that may necessitate a repeat biopsy to guide subsequent therapy. Here we describe the use of blood based, non-invasive technologies to overcome tissue based genomics.


Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonHigh-Value DiagnosticsSELECTBIOenquiries@selectbiosciences.com